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KEY POINTS
 Genetic testing can be used as an instrument for breeding against hereditary genetic skin
diseases in horses.
 Genetic tests are available for hereditary equine regional dermal asthenia, warmblood
fragile foal syndrome, junctional epidermolysis bullosa, incontinentia pigmenti, and
hypotrichosis.
 Insect bite hypersensitivity is a common complex disease affected by several genes (poly-
genic inheritance) and environmental factors.
 Genomic technologies emerge as a useful tool to understand the genetics behind com-
mon complex skin diseases.
 Horse can serve as an animal model for the human skin conditions.INTRODUCTION
Structure and Function of the Skin
Skin displays an astonishing diverse set of phenotypes and physiologic functions
ranging from skin and hair color to immune function. Acting as a primary barrier be-
tween the body and its environment, its key functions are (1) to prevent environmental
compounds from permeating into the epidermal and dermal layers, giving rise to an
immune response and (2) to restrain excessive water passage from one side to the
other of the epidermis, in particular providing an effective barrier to the loss of water.
Skin functions as an immunologic barrier and is often the first organ to connect to
adverse allergens. It is an immunologic organ, nominated as a peripheral lymphoid
organ that contains several important types of immunocompetent cells in both
epidermis and dermis.1–3 The immune competence in epidermis is mainly mediateda DepartmentofAnimal Breeding andGenetics, SwedishUniversity ofAgricultural Sciences, Almas
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Lindgren et al324by keratinocytes secreting immunoregulatory compounds and antigen-presenting
Langerhans cells, whereas in the deeper layer dermis cells such as assorted dendritic
cells, mast cells, and T-cell subsets play a crucial role.1 As a group, these well-
organized cells mediate cutaneous immunosurveillance. It can be expected that im-
mune reactions in the skin are equally important to those occurring within classical
lymphoid organs in protection from harmful foreign substances. Further, skin provides
sensory perception for touch and pain, temperature regulation, and pigmentation and
produces structures such as hair and hoof.
Mammal skin is a multicellular organ, and itsmorphogenesis includes expression of
multiple genes in a coordinated fashion. The anatomic structures of equine skin have
been reported in multiple studies4–7 (Fig. 1). Skin is generally composed of 2 layers,
the outer nonvascular epidermis and the inner vascular and sensitive dermis. In hors-
es, the epidermis consists of 5 to 7 cell layers, excluding the horny layer in haired body
skin, that are constantly multiplying from its deeper layers and eventually drop off at
the surface.6,8 The most abundant cell type of the epidermis is keratinocytes (about
85%).6,9 The dermis is mostly composed of connective tissue and account for most
of the strength and elasticity of the skin. It composes an interconnected mesh of
elastin and collagenous fibers, produced by fibroblasts. Normally the dermis is
sparsely populated with cells; however, fibroblasts, dermal dendrocytes, and mast
cells are present throughout with varying density.5,8,10 Melanocytes are most
commonly present in the basal layer of epidermis; however, these cells can also be
present in the superficial layers of dermis in strongly pigmented skin. The dermis
also supports and maintains many other structures, such as blood and lymph vessels,
hair follicles, muscles, nerves, and glands (sweat and sebaceous). In horses, the gen-
eral skin thickness varies over the body (eg, thickest on the forehead, dorsal neck, dor-
sal thorax, rump, and base of the tail),8 with the average thickness of the mane and tail
epidermis being 91 mm versus 53 mm for the epidermis of the general body skin under
the coat.8
Under normal circumstances, hair growth occurs in a cycle, rather than continuous
growth.11 Hair follicles are the structures that contain the roots of the hair and consist
of 5 major components: the dermal hair papilla, the hair matrix, the inner root sheath,
the outer root sheath, and the hair shaft itself.12 There are 3 main phases of the hair
growth cycle: anagen, catagen, and telogen. Anagen is the growing stage whereFig. 1. Lip skin biopsy from a healthy horse. (A) Skin structure: epidermis and dermis
including hair follicles (light microscopy X1). (B) Zoom of the dermis hair follicles (light mi-
croscopy X4). (Courtesy of Eva Hellme´n, DVM, Professor, Dipl. ECVP. Swedish University of
Agricultural Sciences, Department of Anatomy, Physiology and Biochemistry, Uppsala,
Sweden.)
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stage where a constriction of the hair bulb takes place and the distal follicle becomes
broad and presses the hair outward. Telogen is the resting stage where a secondary
germ is formed. The hair growth continues until it attains its predetermined length, a
mechanism that is under genetic regulation. Knowledge of the genetic factors that
regulate the hair cycle is limited. Equine mane hairs are similar to human scalp hairs
because they grow to a greater length than the body hairs, that is, mane hairs have
a long anagen growth phase. Periodic molting of hairs allows the pelage to adapt to
seasonal changes. Shedding is predominantly influenced by photoperiod and affects
the hairs of the body, whereas hairs of the mane, tail, and fetlock are basically exempt
from such regulation.12
Role of Genetics in Skin Morphogenesis and Disease
The process of generating the anatomic structures of the equine skin has, to the au-
thors’ knowledge, not been reported. However, information on skin morphogenesis
in other domestic mammals and human is available.12 In mammals, distinct signaling
patterns specify different developmental stages that ensure correct morphogenesis
of skin and its associated structures such as hair and hoof.13,14 The whole process
requires a tightly controlled sequence of signaling events. Because genetics regulate
organ development, and adult phenotypes are usually defined during development,
investigations on differences in gene expression, contribution of new genes,
changes in alternative splicing, and role of regulatory RNAs (long noncoding RNA
[lncRNA] and microRNA [miRNA] [Box 1]) are important to understand phenotypic di-
versity such as disease. Genetic regulation of mammalian organ development/
morphogenesis is only partly understood.15–17 For instance, the contribution of
lncRNAs to organ development remains vastly unexplored in mammals, including
horses.
Since the onset of domestication, horses have been strongly selected for speed,
strength, gaits, and endurance-exercise traits. The development of specific horse
breeds has resulted in the selection for athletic phenotypes that enable the use of
horses for riding, racing, and recreation, with clear differences in morphology and
behavior. The breed formation process has also enriched different horse breeds forBox 1
Definitions of biological terminologies
Morphogenesis: the developmental process of the shape/morphology of an organism.
lncRNA: long (200 bp) nonconding RNAs are molecules that are not translated to proteins. They
play a role in the regulation of gene expression.
miRNA: micro (w20 bp) RNA are shorter than lncRNA but also function in regulating gene
expression.
Genome-to-phenome research: the study of the link between the DNA sequence (genome) and
the different phenotypic characteristics (phenome) of an organism.
GWAS: a genome-wide association study is an approach used to investigate the association of a
specific trait (a phenotype such as a shape or disease) to its causative genetic variants.
SNP: a single nucleotide that is polymorphic in a population.
Epistasis: is when the effect of one gene depends on the effect of another gene.
Breeding value: the value of an individual animal in a breeding program for a specific trait. An
animal’s expected breeding value is the sumof the halves of the breeding values of each parent.
Lindgren et al326disease mutations, and sometimes these mutations are breed specific. Disease muta-
tions in horses offer the advantages of spontaneous disease models.
This review on equine genetic skin disease aims to present some of the latest ad-
vances in genome-to-phenome research in a nonmodel species of both medical
and agricultural interest. It will summarize equine skin disease for which genetic tests
are available and discuss their potential role as a complementing diagnostic tool.
Genetic testing as an instrument for breeding against genetic skin diseases in horses
will also be outlined. The review ends with perspectives on future studies in relation to
these skin diseases.
Insect Bite Hypersensitivity
Insect bite hypersensitivity (IBH) is the most common allergic skin diseases in horses
worldwide. The allergic reaction is toward the biting midges Culicoidesspp, but other
insects can also be involved or be cross-reactive.18 The acute stage of the disease in-
volves an immunoglobulin E (IgE)-mediated type I hypersensitivity reaction, but a
delayed type IV hypersensitivity reaction is likely present during the chronic stages
of the disease. The clinical signs are gradual in onset and seasonally recurrent
because the insects only live during the warm period from spring to autumn. The
symptoms are severe pruritus in the mane and tail, leading to self-excoriations and
secondary changes in the skin including crusted papules, hyperkeratosis, lichenifica-
tion with thickening of the skin, diffuse to complete alopecia, and ulcerations (Fig. 2).
The lesions can also be seen in the face and ears, at the chest and/or ventrum, in the
axillae, and at the hips.19
All breeds can develop IBH and the prevalence has been calculated as a wide
range, between 3% and 60% in different studies.20–23 The Icelandic horse is particu-
larly affected because the midges do not exist in Iceland and the horses get sensitized
when exported abroad. The higher prevalence for Icelandic horses exported to the
continent has been demonstrated in several studies and shows that the exposure to
the midges is essential for development of IBH. It also shows that the prevalence
for Icelandic horses born outside Iceland does not differ very much from other breeds,
with figures between 6.7% and 8%.20,22 The heritability in various breeds ranges from
0.16 to 0.30.24 Heritability was estimated to be 0.16 in Friesian horses, 0.24 in Dutch
Shetland ponies, and 0.27 in Icelandic horses.24–26 When severity was taken into ac-
count in the Swedish study of Icelandic horses, heritability was estimated at 0.30. In
the same study, offspring from mares with IBH demonstrated a higher risk of devel-
oping the disease. The prevalence was in the range of 0% to 30% in different paternal
half-sib groups, which clearly shows the difference on an individual level in the herita-
bility of the disease.24
At this time, there are no validated tests for the diagnosis of IBH. Therefore, the diag-
nosis is clinical and involves ruling out other pruritic diseases such as parasites,
together with the typical clinical presentation of seasonal recurrent pruritus in the
mane and tail. Intradermal skin tests or serology tests for antigen-specific IgE have
been used to identify allergens involved in the allergic reaction, but several studies
have shown that the available tests have low sensitivity and/or specificity and are
not standardized.27,28
In the 1990s, it was determined using serology that certain major histocompatibility
complexes (MHC), that is, equine leukocyte antigen (ELA) specificities, were linked to
IBH susceptibility.20,29,30 Later, DNA genotyping, as a substitute for ELA serology,
showed that the ELA class II region in horses was associated with IBH susceptibility.31
The same ELA class II risk factors were shown to contribute to equine IBH in 2 distinct
horse breeds, Icelandic horses and Exmoorponies.31 Yet another study found
Fig. 2. Clinical signs of IBH. (A, B) Alopecia, broken hairs, and focal ulcerations in the mane.
(C, D) Alopecia, hyperpigmentation, and lichenification at the base of the tail and in the
mane. (Courtesy of Rebecka Frey, DVM, AniCura Norsholms Djursjukhus, Norsholm, Sweden.)
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Icelandic horses.32 However, this study also identified susceptibility to IBH in 4 candi-
date allergy-related genes: CD14 receptor (CD14), interleukin 23 receptor (IL23R),
thymic stromal lymphopoietin (TSLP), and transforming growth factor beta 3
(TGFB3).32 Because the genomic structure of the horse MHC class II region has been
resolved,33,34 it may now be possible to fine map the responsible susceptibility risk fac-
tors. The MHC haplotype diversity was recently determined in Icelandic horses, which
should further facilitate gene mapping within the region in this particular breed.35
With the overall goal to both breed against IBH and improve the health and welfare of
IBH-affected horses via development of new treatments, several studies had the aim to
scan the whole equine genome to identify susceptibility genes. Genome-wide associa-
tion studies (GWAS) using large numbers of single nucleotide polymorphisms (SNPs) in
cases and control animals have most frequently been used for this purpose. The first
GWAS on IBH in horses was performed on Shetland pony mares living in the
Netherlands.36 Significant associations to IBH were detected on 12 chromosomes,
including ECA20, where ELA is located. Subsequently, several GWAS for IBH have
been performed within Icelandic horses, Exmoor ponies, Friesian horses, and Belgian
Warmbloodhorses37–42 (Table 1). One of these GWAS was performed using both
Table 1
Summary of genomic regions identified in genome-wide association studies on insect bite
hypersensitivity
Method (Array) Breed
GWAS
Windows
Hits
Overlapping
Windows
Hitsa ELA References
Case-control GWAS (70K) Icelandic horse 20 9 Yes Schurink et al,36
2012
Case-control GWAS (50K) Icelandic horse 29 6 No Shrestha et al,38
2015
Case-control GWAS
(50K & 70K)
Icelandic horse 30 12 No Shrestha et al,42
2019
GWAS IgE levels (70K) Icelandic horse 35 8 Yes Franc¸ois et al,41
2019
Case-control GWAS (70K) Shetland pony 20 8 Yes Schurink et al,36
2012
Case-control GWAS (50K) Shetland pony 18 5 No Schurink et al,37
2013
GWAS IgE levels (70K) Shetland pony 35 5 Yes Franc¸ois et al,41
2019
Case-control GWAS (670K) Exmoor pony 24 4 Yes Velie et al,39
2016
Chi-square test (TaqMan
assay)
Exmoor pony 2 2 No Shrestha et al,42
2019
Case-control SNP- & CNV-
based GWAS (670K)
Friesian horse 23 6 Yes Schurink et al,40
2018
GWAS IgE levels (670K) Belgian
Warmblood
horse
35 5 No Franc¸ois et al,41
2019
a Comparison with recent bibliography up to 2019.36–42
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both types of genetic markers were able to identify a clear association between the
ELA region and IBH susceptibility in Friesian horses.40 Recently, in an attempt to
improve the power to identify underlying genetic variants for IBH, an objective diagnosis
of horses with and without IBH was performed using IgE levels against several recom-
binantCulicoides spp. allergens.41 The study was performed in Shetland ponies, Icelan-
dic horses, and Belgian Warmblood horses. Several chromosome regions could be
detected that confirmed previously IBH-associated regions, but novel regions were
also identified. The use of allergen-specific IgE levels as a quantitative phenotype had
an added value because a larger number of associations were obtained, as compared
with a binary case-control design using the same horse material.
In summary, breed differences in susceptibility to IBH exist, although a common ge-
netic background is present to some extent among certain breeds. The overall conclu-
sions from these genomic studies are that IBH is a complex disease that involves the
additive effects of many genes and the interplay between genetic and environmental
factors (see Table 1).
Melanoma and Vitiligo
Melanomas in horses appear as black lumps or nodules most commonly near hairless
areas, such as under the tail, around the anus, or in the sheath of geldings. They can
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malignant by aging. The melanomas occur in higher frequency in gray-colored horses,
and around 80% of all greying horses will get melanomas by 15 years of age. The diag-
nosis is made by fine-needle aspiration or biopsy of the nodules. Vitiligo is a disease
that leads to depigmentation of the skin due to destruction of melanocytes and as a
result the hairs turn white. It presents as small, focal, and often well-circumscribed
white spots in the coat or at mucocutaneous junctions. Arabian fading syndrome is
a form of vitiligo that develops in young Arabians by 1 to 2 years of age. All colors
in the breed can have vitiligo, but it is more common in horses with gray hair coat. It
is characterized by round depigmented macules that coalesce to patches, around
the eyelids, lips, and muzzle and occasionally around the genitalia. There is no visible
inflammation of the skin, and the horse has no other symptoms. The depigmentation
can wax and wane in intensity but is usually permanent. The diagnosis is done by clin-
ical picture and biopsy for histopathology.
Melanoma and vitiligo-like depigmentation are among the most common skin dis-
eases in gray horses and they can reach a prevalence between 10% and 80%,
depending on the horse’s age or breed.43–46 Malignancy of melanomas in solid
colored horses is more severe than in gray horses,47 although metastases in the lymph
nodes, liver, spleen, skeletal muscle, lungs, and surrounding or within blood vessels
may occur in gray horses.48 In 2008, a 4.6 kb duplication in the STX17 (syntaxin 17)
gene was identified as the cause of gray phenotype.49 This duplication, therefore,
was proposed to be involved in the promotion of melanocyte proliferation by upregu-
lating the expression of STX17 and/or NR4A3 (nuclear receptor subfamily 4, group A,
member 3) genes. The region contains regulatory elements with melanocyte-specific
effects (microphthalmia-associated transcription factors), and higher copy number of
the STX17 duplication is present in aggressive tumors of gray horses.50,51 However,
the mechanistic features of the duplication remain unknown. Moreover, RACK1 (re-
ceptor for activated C kinase 1) protein stands as a candidate molecular marker for
the veterinary diagnosis of malignant melanocytic tumors in horses.52
Recent studies in Spanish Purebred horses and derived breeds such as the Old Kla-
drubers or the Lipizzaners indicate that there is a genetic link between melanoma and
vitiligo.45,53,54 Although varying between breeds, the heritability of vitiligo (h2 5 0.20–
0.63) is higher than melanoma (h2 5 0.07–0.37).45,53,54 Either melanoma or vitiligo
predisposition is known to have complex inheritance patterns with polygenic and
pleiotropic effects involved. In this sense, Curik and colleagues53 (2013) demonstrated
that these diseases are influenced by few genes of moderate-to-large effects
(eg, STX17 and ASIP [agouti signaling protein]), as well as a large number of genes
with small additive effects, influenced by genes of moderate-to-large effects.
However, the study has been limited to investigate the patterns of inheritance and
therefore causal mutations have not been yet determined.
The availability of whole genome sequences within the emerged “genomic era” has
afforded the opportunity to develop a next-generation high-density SNP array for the
domestic horse in 2017.55 Numerous genome studies have been performed in large
sample designs on many different traits; however, none of the studies reported novel
insights into the underlying molecular processes of melanoma and vitiligo diseases in
horses. However, a recent study in the Lipizzaner horse identified a common long
overlapping homozygous region on ECA14:34.05–35.18 Mb (EquCab2.0), which con-
tains several genes involved in melanoma metastasis and survival rate of melanoma
patients in humans (eg, SPRY4 [sprouty RTK signaling antagonist 4] and HSP90AB1
[heat shock protein 90 alpha family class B member 1]).56 Overall, this approach
allowed the identification of potential novel genomic regions that may play a role in
Lindgren et al330equine melanoma. Further studies including larger cohorts and careful clinical classi-
fication of cases are required to better understand the complex genetic and molecular
mechanisms leading to skin diseases.
Ehlers-Danlos Syndrome Subtypes: Hereditary Equine Regional Dermal Asthenia
and Warmblood Fragile Faol Syndrome
Ehlers-Danlos syndrome (EDS) comprises a group of genetically heterogeneous
connective tissue disorders linked with genetic defects affecting collagen or other
extracellular matrix proteins.57 In horses, EDS subtypes include different inherited
connective tissue disorders clinically characterized by skin fragility and hyperextensi-
bility.58 To date, 2 EDS subtypes have been described based on causative genetic
mutations, hereditary equine regional dermal asthenia (HERDA),59,60 and Warmblood
fragile foal syndrome (WFFS).61,62
Hereditary Equine Regional Dermal Asthenia
HERDA, also known as hyperelastosis cutis, is a subtype of EDS disorder classified as
degenerative skin disease with an autosomal recessive inheritance predominantly
observed in the American Quarter Horses.59 The defect is in the collagen fibers in
the skin and leads to a separation between the epidermis and dermis. The symptoms
often start when the horse is broken in to a saddle at around 2 years of age. The pres-
sure from the saddle causes the skin to tear and can lead to wounds with prolonged
healing time, which may develop into disfiguring scars. The skin is loose and hypere-
lastic in affected horses.63
The disease has a prevalence of 3.5% within the general Quarter Horse population,
but it is much more prevalent within the cutting horse industry (up to 28%) or within
pleasure/working-cow horses (carrier frequency rates of 12.8% and 11.5%, respec-
tively).64 A whole-genome scan approach was used to identify a homozygous
missense mutation in exon 1 of PPIB (peptidylprolyl isomerase B) gene (c.115G > A)
in affected HERDA horses.59 The gene acts as a chaperon involved in proper folding
of collagens, and the mutation affects collagen folding and secretion by a decrease in
hydroxylysine and glucosyl-galactosylhydroxylysine in affected horse fibroblasts.60
However, not all horses displaying an EDS phenotype have a mutation in the PPIB
gene, suggesting genetic heterogeneity of EDS disorders.65,66
Warmblood Fragile Foal Syndrome Type 1
WWFS is another subtype of EDS disorder of autosomal recessive inheritance charac-
terized as a fatal defect of the connective tissue involving severe skin malformations in
neonatal foals, pronominally observed in Warmblood horses and related breeds.61,62
The disease has a carrier frequency in normal adult Warmblood population around
w11%.62,67 WFFS is caused by a mutation in the PLOD1 (procollagen-lysine, 2-oxo-
glutarate 5-dioxygenase 1) gene (c.2032G > A), which codes for an enzyme important
for collagen biosynthesis.62
In summary, 2 different genetic tests are available for the diagnosis of HERDA and
WFFS EDS subtypes (Table 2). However, a new case of EDS observed in a
Mangalarga–Campolina crossbreed mare with PPIB and PLOD1 mutations tested
negative, indicating that another gene involved in the collagen biosynthesis may be
responsible for other EDS subtypes.58
Chronic Progressive Lymphedema
Chronic progressive lymphedema (CPL) is a disabling skin disorder in draft horse
breeds such as Clydesdales, Shire, and Belgian draft horses.68,69 It starts at an early
Table 2
Summary of mode of inheritance and genetic tests available for equine skin diseases
Disease Breeds
Mode of
Inheritance
DNA Test
Available
Insect bite hypersensitivity Multiple breeds (see Table 1). Higher
prevalence in Icelandic horse
Complex No
Melanoma and vitiligo Gray horses. Higher prevalence in
Iberian horses and related breeds
Complex No
Hereditary equine regional
dermal asthenia
Quarter horse and related breeds Recessive Yes
Warmblood fragile foal
syndrome type 1
Warmblood horses and related
breeds
Recessive Yes
Chronic progressive
lymphedema
Draft breeds Complex No
Junctional epidermolysis
bullosa
Draft breeds, American Saddlebreds Recessive Yes
Incontinentia pigmenti Quarter horse X-linked
dominant
Yes
Hypotrichosis American Bashkir Curly horse,
Missouri Fox trotter, Percheron
draft horse
Complex Yes
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skin changes such as hyperkeratosis and dermal fibrosis with thick skin folds and nod-
ules. Secondary infections contribute to the chronic changes, and the condition gives
rise to severe discomfort to the horse and commonly leads to euthanasia. There
seems to be a genetic predisposition to altered elastin metabolism and impaired func-
tion of the lymphatic system in the extremities.69 The diagnosis is made by clinical pic-
ture and by ruling out primary causes to the skin changes such as Chorioptes.
CPL has been classified as a multifactorial disorder with a prevalence of 96% within
Belgian and someGerman breeds.70 Heritability coefficients for the occurrence of clin-
ical CPL lesions in Belgian Draught Horses have been estimated to be 0.26 for horses
older than 3 years.71 Genetic components are therefore likely to play a role in this dis-
ease. However, none of the potential candidate genes known to affect lymphedema-
distichiasis syndrome and Darier-White disease (Keratosis follicularis) in humans (eg,
FOXC2 [Forkhead box C2] and ATP2A2 [ATPase sarcoplasmic/endoplasmic reticulum
Ca21 transporting 2]) are associated to CPL in horses.72,73
A whole-genome scan performed across several draft horse breeds affected by
CPL identified significant quantitative trait loci on ECA1, 10, and 17.74 The study pro-
posed several potential candidate genes involved in the regulation of inflammatory
autoimmune responses (eg, UBE3A [ubiquitin protein ligase E3A], CD109 [CD109
molecule], and MTMR6 [myotubularin-related protein 6]), which will require further
functional analysis to confirm whether any of these genes are truly associated with
clinical signs observed with CPL. Another GWAS for CPL in Friesian horses did not
achieve any genome-wide significance.75 However, recent findings in the Belgian
Draught horse identified several regions surpassing nominal significance with candi-
date genes described in previous studies on CPL (eg, FOXC2, UBE3A, or CD109).
The study confirms the involvement of several processes of the immune response,
thereby supporting the hypothesis to consider CPL as an inflammatory autoimmune
response.76 Further functional research is needed to identify the genetic cause under-
lying CPL and the involvement of the immune response.
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Junctional epidermolysis bullosa (JEB) is a severe skin blistering disease of genetic
origin that affects newborn foals. It has an autosomal recessive mode of inheritance
and has been found in the Belgian, Italian, and French draft horses and in American
Saddlebred horses (see Table 2).77–84 It is a mechanobullous disease that leads to
the development of ulcers and blisters in the skin, most commonly at pressure points
including the hocks or the stifle and at mucocutaneous junctions such as the mouth
and anus. The defect leads to a separation between the skin layers, and only minor
trauma leads to severe detachment of the skin and even sloughing of the hoof wall.
The foals can also have oral abnormalities with premature eruption of the teeth and
loss of enamel that cause bleeding in the mouth. This disease was first called epithe-
liogenesis imperfecta, but when it was shown that it involved a defect in the lamina
propria, it was renamed as JEB. The pathologic signs of JEB closely match what
can be observed in Herlitz junctional epidermolysis bullosa in humans, although in
horses, the dense hair may act as a protection against trauma.79 There is no treatment
of JEB, and the foals are euthanized because of animal welfare reasons. The diagnosis
can be made from biopsy of intact blisters (macroscopic, histologic, and ultrastruc-
tural) or genetic testing in draft and American Saddlebred horses.
Two mutations that affect the dermal-epidermal junction have been identified in
horses: one large deletion in LAMA3 (laminin subunit alpha 3) in American Saddlebred
horses and an insertion (1368insC) in LAMC2 (laminin subunit gamma 2) in Belgians
and other draft horse breeds.79,80,84 The deletion in American Saddlebred horses is
6589 base pairs and span exons 24 to 27 in LAMA3. The mutations affect the
anchoring fibril laminin 5 protein located in the basement membrane in the dermal-
epidermal junction. Laminin 5 is a heterotrimeric basement membrane protein that
consists of 3 glycoprotein subunits—the a3, b3, and g2 chains—that are encoded
by the LAMA3 (laminin subunit alpha 3), LAMB3 (laminin subunit beta 3), and
LAMC2 (laminin subunit gamma 2) genes, respectively.84 Identification of healthy car-
riers is important to prevent the spread of this disease.Incontinentia Pigmenti
Incontinentia pigmenti (IP) is a congenital skin disorder characterized by abnormalities in
the skin but also other structures of ectodermal origin as the teeth and eyes. Based on a
single pedigree consisting of 23 horses, the disorder follows an X-linked dominant inher-
itance pattern, where affected males are aborted and only affected females survive (see
Table 2). The foals develop exudative and pruritic skin lesions soon after birth. These
develop to wartlike lesions, and healing is seen as alopecia or occasional wooly hair
regrowth. Additional symptoms include dental, hoof, and ocular developmental anom-
alies.85 Horses with IP in this pedigree display many similarities to human IP.85
Human familial IP also segregates as an X-linked dominant disorder and is usually
lethal prenatally in males. The condition predominantly affects the skin. Cells express-
ing the mutated X chromosome are eliminated selectively around the time of birth, so
females with IP exhibit extremely skewed X-inactivation.86 Infants usually have a blis-
tering rash that heals and develops into wartlike skin growths. Hyperpigmentation in a
swirled pattern occur in early childhood. In humans, dental, eye, hair, and nail abnor-
malities can occur.86
In human, IP is caused by a mutation in the IKBKG (inhibitor of nuclear factor kappa
B [NFkB] kinase subunit gamma) gene. The gene is found on the X chromosome
(Xq28) and codes for the protein NFkB’s essential modulator (IKK-gamma, formerly
called NEMO) found in almost all cells of the body. The function of the IKK-gamma
Genetics of Skin Disease in Horses 333protein is to activate the protein NFkB inside the cell. NFkB then migrates into the cell
nucleus and in turn activates genes that are important for, among other things, fetal
development and the function of the immune system.
The IKK-gamma protein is needed for the organism to develop properly, control cell
growth and death, and protect cells from infection. This is important, for example, in
the early fetal development of ectodermal tissues such as skin, nails, and hair, as
well as parts of the central nervous system and the immune system. The most com-
mon mutation that causes IP implies a complete loss of function of the protein.
In horses, a nonsense mutation (c.184C > T, p.Arg62*) in IKBKG has been identified
in mares with IP.85 This was achieved by whole-genome resequencing (WGS) of one
affected mare and comparison with WGS data from 44 control horses from 11 breeds.
The variant is predicted to result in a premature stop codon and truncates approxi-
mately 85% of the protein.85 Since a homologous mutation (p.Arg62*) has been
observed in a human IP patient, horses with the same variant can serve as an animal
model for the human condition.
Hypotrichosis
Hypotrichosis implies a less than normal amount of hair. The condition results in alo-
pecia that is apparent at birth or develops during the neonatal period and can be asso-
ciated with defects in other ectodermal structures such as teeth, hooves, eyes, or
sweat glands. It is a genetic disease seen predominantly in the curly coated breeds
American Bashkir Curly horses and Missouri Fox trotters. The breeds have normal
shedding periods, but, in some individuals, there are permanent hair loss of the
mane and tail. It is seen as diffuse to complete alopecia due to dysplasia of hair folli-
cles. Horses with incomplete hypotrichosis are presented with broken hairs and shed-
ding of hairs at the lateral upper tail and at the forelock.
Congenital progressive hypotrichosis has been reported in a blue roan Percheron
draught horse.87 This horse was born with patchy alopecia of the trunk and legs
and at 5 years of age the body hair was almost absent (mane and tail hairs were pre-
sent, but sparse). There were no abnormalities of the teeth and hoof. Histopathology
revealed follicular hypoplasia and hyperkeratosis, as well as an excess of catagen and
telogen hair follicles.
Curly coated horse breeds present an exceptional coat that vary in curliness of the
body, mane, tail, and ear hairs. Both autosomal recessive and dominant inheritance
patterns have been suggested to explain the diversity of the curly phenotype.88,89 A
GWAS study of 70 curly and straight-haired North American and French horses hy-
pothesized to carry the dominant curly hair trait has been performed.90 By using
WGS, the study identified a missense variant (g.21891160G > A, p.R89H) in the
coil 1A domain of the KRT25 (keratin 25) gene to be associated with the dominant
curly phenotype. The variant was confirmed by genotyping additional 150 curly
and 203 randomly chosen straight-haired animals from 35 different breeds. Five
discordant curly horses were observed, and sequencing 2 of those horses suggests
locus heterogeneity for the dominant curly phenotype within North American Curly
horses.90
Hypotrichosis is not observed in all curly coated horses. Therefore, a research team
aimed at investigating the genetic component of curly coat with and without hypotri-
chosis.91 A GWAS analysis identified significant signals on chromosome 11. WGS
data detected 2 variants in the region within KRT25 and SP6 (transcription factor
Sp6) that could explain all hair phenotypes. Curly coat with no hypotrichosis was pre-
sent in horses carrying only the SP6 variant. However, a variant allele of the KRT25
gene was found to be epistatic to SP6, where horses carrying the KRT25 variant
Lindgren et al334(heterozygous or homozygous state), regardless of their SP6 genotype, exhibited a
curly hair phenotype with incomplete or complete hypotrichosis, respectively.
Future Directions
Understanding the molecular basis of mammalian phenotypic traits is a fundamental
biological goal and is primarily important for understanding the development of dis-
eases. Equine skin diseases are common, and the interest in equine dermatology is
therefore increasing.92 For instance, 80% of gray coat horses will develop melanoma
after 15 years of age, and up to 60% of horses are susceptible to IBH. Often, there is a
genetic component involved in skin disease development, as presented in this article.
Notably for monogenic traits where the causative mutation has been identified,
genetic testing can serve as a complementing diagnostic tool and could also, when
relevant, guide early treatment. However, in domestic animals, genetic testing is of
particular value for informed breeding decisions. For instance, genetic testing of a
monogenic trait enables identification of healthy carriers of recessive disease alleles
(eg, the EDS subtypes HERDA or WFFS).
For complex traits, genomic selection is a more suitable approach. Genomic selec-
tion, a form of marker-assisted selection in which genetic markers covering the entire
genome are used, is rapidly increasing in importance in other species.61,72 The basic
concept of genomic selection is to combine whole-genome molecular markers with
phenotypic and pedigree data in an attempt to increase the accuracy of prediction
for breeding values. Genomic selection can be especially valuable for traits that are
difficult to measure in large scale, and for lower-heritability traits, such as IBH.
Genomic selection using only significantly disease-associated markers or all
markers could increase the efficiency of breeding for decreased IBH disease preva-
lence.36 This would be of particular value because it can be applied at a young age
of the horse, before any mating occurs, as well as because the occurrence of IBH
in individual horses highly depends on the exposure to Culicoides spp.
Disease mutations may reside either within the coding part of a gene or in a unit that
regulates the disease-associated gene. The regulation of gene activity may disrupt
protein production and cell processes and result in disease. Therefore, it is important
to link variations in the expression of certain genes to the development of each genetic
skin disease. A continued focus is to develop and apply genome-based strategies for
the early detection, diagnosis, and treatment of equine skin disease. Breeding against
genetic disease is an efficient and cost-effective strategy for the management of the
disease severity levels, with particular interest in complex traits such as IBH, CPL,
or melanoma.
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